MCL Literature Feed
9 papers on mantle cell lymphoma from PubMed. Updated daily.
In the BRUIN study, relapsed/refractory MCL patients previously treated with a BTKi maintained or improved quality of life and symptoms on pirtobrutinib, supporting its favorable long-term tolerability.
This study demonstrates the feasibility of administering brexucabtagene autoleucel in an outpatient setting for MCL, a significant shift that could improve patient convenience and reduce healthcare costs.
A 2022 real-world Japanese study shows chemotherapy remains dominant frontline while BTKis are common second-line, with physicians prioritizing quality of life for BTKi-treated patients over tumor response.
This review highlights using geriatric assessments to guide therapy selection and proactively manage toxicities in older MCL patients, aiming to optimize outcomes and avoid over- or undertreatment.
Experienced nurses and advanced practice providers outline key considerations for implementing a successful outpatient lisocabtagene maraleucel CAR-T program, offering a practical framework for managing MCL patients.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
Ibrutinib oral suspension has comparable bioavailability to tablets/capsules and is compatible with enteral tubes, providing a crucial administration option for MCL patients with dysphagia or requiring tube feeding.
A qualitative study of Japanese MCL patients reveals that convenience, quality of life, and shared decision-making are key treatment preferences, alongside efficacy and safety, guiding personalized care.
This large SEER database study identifies being unmarried, particularly widowed, as an independent negative prognostic factor for survival in MCL, underscoring the need for enhanced psychosocial support.
This study developed and validated a new lymphoma-specific patient-reported outcome measure using the EORTC Item Library, providing a crucial tool for assessing MCL symptoms in clinical trials.